Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (30)
Federica Mescia, Chiara Salviani, Mattia Tonoli, Stefania Affatato, Daniele Moratto, Martina Tedesco, Alice Guerini, Alessia Gemmo, Marta Camoni, Elisa Delbarba, Roberto Zubani, Emirena Garrafa, Marco Chiarini, Gina Gregorini, Francesco Scolari & Federico Alberici. (2023) Sustained post-rituximab B-cell depletion is common in ANCA-associated vasculitis and is affected by sex and renal function. Nephrology Dialysis Transplantation.
Crossref
Crossref
Kotaro Matsumoto, Katsuya Suzuki, Hidekata Yasuoka, Junichi Hirahashi, Hiroto Yoshida, Mayu Magi, Mariko Noguchi-Sasaki, Yuko Kaneko & Tsutomu Takeuchi. (2023) Longitudinal monitoring of circulating immune cell phenotypes in anti-neutrophil cytoplasmic antibody-associated vasculitis. Autoimmunity Reviews 22:3, pages 103271.
Crossref
Crossref
Mohammad Amin Habibi, Samira Alesaeidi, Mohadeseh Zahedi, Samin Hakimi Rahmani, Seyed Mohammad Piri & Soheil Tavakolpour. (2022) The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review. Biology 11:12, pages 1767.
Crossref
Crossref
Lucia Del Vecchio, Marco Allinovi, Paolo Rocco & Bruno Brando. (2021) Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?. Journal of Clinical Medicine 10:24, pages 5847.
Crossref
Crossref
Jun Li, Yuehong Li, Suhong Sun, Liwen Yang, Long Ma, Bin Shi, Rui Ma & Xinsheng Yao. (2021) Characterizing the BCR repertoire during lymphocyte reduction and recovery mediated by cyclophosphamide and granulocyte-macrophage colony-stimulating factor. International Immunopharmacology 101, pages 108292.
Crossref
Crossref
Yi Han Chen, Xin Yu Wang, Xin Jin, Zi Yang & Jianguang Xu. (2021) Rituximab Therapy for Primary Sjögren’s Syndrome. Frontiers in Pharmacology 12.
Crossref
Crossref
Larissa Valor-Méndez, Arnd Kleyer, Jürgen Rech, Bernhard Manger & Georg Schett. (2021) Long-term B-lymphocyte depletion and remission of granulomatosis with polyangiitis after two courses of rituximab treatment. Rheumatology 60:5, pages e162-e164.
Crossref
Crossref
Salem Almaani, Lynn A. Fussner, Sergey Brodsky, Alexa S. Meara & David Jayne. (2021) ANCA-Associated Vasculitis: An Update. Journal of Clinical Medicine 10:7, pages 1446.
Crossref
Crossref
Filippo Fagni, Federica Bello & Giacomo Emmi. (2021) Eosinophilic Granulomatosis With Polyangiitis: Dissecting the Pathophysiology. Frontiers in Medicine 8.
Crossref
Crossref
Zachary C. Stensland, John C. Cambier & Mia J. Smith. (2021) Therapeutic Targeting of Autoreactive B Cells: Why, How, and When?. Biomedicines 9:1, pages 83.
Crossref
Crossref
S. Shahzad Mustafa. 2021. Primary and Secondary Immunodeficiency. Primary and Secondary Immunodeficiency
363
380
.
Laura S. van Dam, Jelle M. Oskam, Sylvia W. A. Kamerling, Eline J. Arends, O. W. Bredewold, Magdalena A. Berkowska, Jacques J. M. van Dongen, Ton J. Rabelink, Cees van Kooten & Y. K. Onno Teng. (2020) Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients. Frontiers in Immunology 11.
Crossref
Crossref
S. Shahzad Mustafa, Saad Jamshed, Karthik Vadamalai & Allison Ramsey. (2020) The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab. Clinical Lymphoma Myeloma and Leukemia 20:9, pages e590-e596.
Crossref
Crossref
A. Richard Kitching, Hans-Joachim Anders, Neil Basu, Elisabeth Brouwer, Jennifer Gordon, David R. Jayne, Joyce Kullman, Paul A. Lyons, Peter A. Merkel, Caroline O. S. Savage, Ulrich Specks & Renate Kain. (2020) ANCA-associated vasculitis. Nature Reviews Disease Primers 6:1.
Crossref
Crossref
Alexandre KarrasHélène LazarethSophie Chauvet. (2020) B-cell treatment in ANCA-associated vasculitis. Rheumatology 59:Supplement_3, pages iii68-iii73.
Crossref
Crossref
Etienne Crickx, Jean-Claude Weill, Claude-Agnès Reynaud & Matthieu Mahévas. (2020) Anti-CD20–mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives. Kidney International 97:5, pages 885-893.
Crossref
Crossref
Kentaro Kuzuya, Takayoshi Morita & Atsushi Kumanogoh. (2020) Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis—a meta-analysis. RMD Open 6:1, pages e001195.
Crossref
Crossref
Jens Vikse, Kristin Jonsdottir, Jan Terje Kvaløy, Klaus Wildhagen & Roald Omdal. (2019) Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases. Rheumatology International 39:6, pages 1083-1090.
Crossref
Crossref
Sonali Wijetilleka, Chetan Mukhtyar, David Jayne, Aftab Ala, Philip Bright, Hector Chinoy, Lorraine Harper, Majid Kazmi, Sorena Kiani-Alikhan, Charles Li, Siraj Misbah, Louise Oni, Fiona Price-Kuehne, Alan Salama, Sarita Workman, David Wrench & Mohammed Yousuf Karim. (2019) Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review. Autoimmunity Reviews 18:5, pages 535-541.
Crossref
Crossref
Kristine Oleinika, Claudia Mauri & Alan D. Salama. (2018) Effector and regulatory B cells in immune-mediated kidney disease. Nature Reviews Nephrology 15:1, pages 11-26.
Crossref
Crossref
Claire Leibler, Anissa Moktefi, Marie Matignon, Céline Debiais-Delpech, Julie Oniszczuk, Dil Sahali, José Cohen, Philippe Grimbert & Vincent Audard. (2018) Rituximab and Fibrillary Glomerulonephritis: Interest of B Cell Reconstitution Monitoring. Journal of Clinical Medicine 7:11, pages 430.
Crossref
Crossref
Gizem Ayan, Sinem Nihal Esatoglu, Gulen Hatemi, Serdal Ugurlu, Emire Seyahi, Melike Melikoglu, Izzet Fresko, Huri Ozdogan, Sebahattin Yurdakul & Vedat Hamuryudan. (2018) Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies. Rheumatology International 38:4, pages 607-622.
Crossref
Crossref
Konstantinos Thomas & Dimitrios Vassilopoulos. 2018. The Microbiome in Rheumatic Diseases and Infection. The Microbiome in Rheumatic Diseases and Infection
445
464
.
Jens Thiel, Marta Rizzi, Marie Engesser, Ann-Kathrin Dufner, Arianna Troilo, Raquel Lorenzetti, Reinhard E. Voll & Nils Venhoff. (2017) B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Research & Therapy 19:1.
Crossref
Crossref
Jessica Day, Vidya Limaye, Susanna Proudman, John D. Hayball & Pravin Hissaria. (2017) The utility of monitoring peripheral blood lymphocyte subsets by flow cytometric analysis in patients with rheumatological diseases treated with rituximab. Autoimmunity Reviews 16:5, pages 542-547.
Crossref
Crossref
Emilio Besada. (2016) Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab. BMC Musculoskeletal Disorders 17:1.
Crossref
Crossref
Marco A. Alba & Luis Felipe Flores-Suárez. (2016) Rituximab as Maintenance Therapy for ANCA Associated Vasculitis: How, When and Why?. Reumatología Clínica (English Edition) 12:1, pages 39-46.
Crossref
Crossref
Marco A. Alba & Luis Felipe Flores-Suárez. (2016) Rituximab como terapia de mantenimiento en las vasculitis asociadas a ANCA: ¿cómo, cuándo y por qué?. Reumatología Clínica 12:1, pages 39-46.
Crossref
Crossref
Emilio Besada & Andreas P. Diamantopoulos. (2015) Does Concomitant Methotrexate During Rituximab Treatment in Granulomatosis With Polyangiitis (Wegener's) Increase the Risk of Severe Infection? Comment on the Article by Azar et al. Arthritis & Rheumatology 67:7, pages 1981-1982.
Crossref
Crossref
C. G. M. Kallenberg & T. Hauser. (2015) B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation.
Crossref
Crossref